Relevance of Biomarkers in the Process of Weaning

The Relevance of Biochemical Markers in the Process of Weaning

The purpose of the study is to examine the relevance of biochemical markers (specific pulmonary and cardiac markers and markers of endogenous stress) in the process of weaning in patients with artificial ventilation.

Study Overview

• Status: Unknown
• Conditions: Duration of Weaning

Detailed Description

Artificially ventilated patients on our intensive care unit will be monitored if specific biomarkers have a relevance in risk stratification, optimizing therapy, outcome and success in the process of weaning. Therefore, consecutively, specific blood parameters will be taken at time of intubation,day 1 of weaning and extubation.

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

Study Locations

• Germany
  • Baden-Württemberg
    • Heidelberg, Baden-Württemberg, Germany, 69120
      • Recruiting
      • Intensive Care Unit, University of Heidelberg
      • Contact: Evangelos Giannitsis, Prof. Dr.; Phone Number: 004962215638686; Email: Evangelos_Giannitsis@med.uni-heidelberg.de

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

consecutively all patients on our intensive care unit who are artificially ventilated

Description

Inclusion Criteria:

• Written informed consent
• Able and willing to understand the protocol
• At least 18 years or older

Exclusion Criteria:

• Not fulfilling inclusion criteria

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
weaning patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
success of weaning	primary outcome measure is the success of weaning during hospital stay. Duration of hospital stay is estimated between 1-60days, in average 30days. Criteria is spontaneous breathing.	participants will be followed for the duration of hospital stay, an expected average of 30days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
follow up	Follow up is done after 12 months to check major adverse cardiac or pulmonary events (death, myocardial infarction, re-hospitalisation)	12 months

Collaborators and Investigators

• Sponsor: Heidelberg University

Study record dates

Study Major Dates

• Study Start: April 1, 2011
• Primary Completion (Anticipated): April 1, 2012
• Study Completion (Anticipated): April 1, 2013

Study Registration Dates

• First Submitted: April 13, 2011
• First Submitted That Met QC Criteria: April 22, 2011
• First Posted (Estimate): April 25, 2011

Study Record Updates

• Last Update Posted (Estimate): April 25, 2011
• Last Update Submitted That Met QC Criteria: April 22, 2011
• Last Verified: March 1, 2011

More Information

Terms related to this study

• Other Study ID Numbers: TnT hs 4